External magnet improves antitumor effect of vinblastine and the suppression of metastasis

Cancer Science

Volumn 100, Issue 8, 2009, Pages 1537-1543

  Dandamudi, Suman ^a   Patil, Vishwesh ^a   Fowle, William ^a   Khaw, Ban An ^a   Campbell, Robert B ^a  

^a NORTHEASTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD31 ANTIGEN; LIPOSOME; MAGNETIC CATIONIC LIPOSOME; UNCLASSIFIED DRUG; VINBLASTINE SULFATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG TARGETING; ENDOTHELIUM CELL; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MAGNETIC FIELD; MALE; MELANOMA; METASTASIS INHIBITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRANSMISSION ELECTRON MICROSCOPY; TUMOR VASCULARIZATION;

ANIMALS; ANTIGENS, CD31; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CATIONS; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; DRUG DELIVERY SYSTEMS; FEMALE; IMMUNOHISTOCHEMISTRY; LIPOSOMES; MAGNETICS; MELANOMA, EXPERIMENTAL; MICE; MICE, SCID; NEOPLASM METASTASIS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; TIME FACTORS; TUMOR BURDEN; VINBLASTINE;

EID: 67650666474     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2009.01201.x     Document Type: Article

References (38)

1. Folkman J. Tumor Angiogenesis. Adv Cancer Res. 1985; 43: 175-203.
2. Chaplin DJ, Dougherty GJ. Tumour vasculature as a target for cancer therapy. Br J Cancer. 1999; 80 (Suppl. 1): 57-64.
3. Denekamp J. Vasculature as a target for tumor therapy. Prog Appl Microcirc. 1984; 4: 28-38.
4. Thurston G, McLean JW, Rizen M et al. Cationic liposomes target angiogenic endothelial cells in tumors and chronic inflammation in mice. J Clin Invest. 1998; 101: 1401-13.
5. Campbell RB, Fukumura D, Brown EB et al. Cationic charge determines the distribution of liposomes between the vascular and extravascular compartments of tumors. Cancer Res. 2002; 62: 6831-6.
6. Strieth S, Eichhorn ME, Sauer B et al. Neovascular targeting chemotherapy: Encapsulation of paclitaxel in cationic liposomes impairs functional tumor microvasculature. Int J Cancer. 2004; 110: 117-24.
7. Widder KJ, Senyei AE, Scarpelli DG. Magnetic microspheres: A model system for site specific drug delivery in vivo. Proc Soc Exp Biol Med. 1978; 158: 141-6.
8. Alexiou C, Arnold W, Klein RJ et al. Locoregional cancer treatment with magnetic drug targeting. Cancer Res. 2000; 60: 6641-8.
9. Babincova M, Altanerova V, Lampert M et al. Site-specific in vivo targeting of magnetoliposomes using externally applied magnetic field. Z Naturforsch [C].2000; 55: 278-81.
10. Kubo T, Sugita T, Shimose S, Nitta Y, Ikuta Y, Murakami T. Targeted systemic chemotherapy using magnetic liposomes with incorporated adriamycin for osteosarcoma in hamsters. Int J Oncol. 2001; 18: 121-5.
11. Nobuto H, Sugita T, Kubo T et al. Evaluation of systemic chemotherapy with magnetic liposomal doxorubicin and a dipole external electromagnet. Int J Cancer. 2004; 109: 627-35.
12. Zhang JQ, Zhang ZR, Yang H, Tan QY, Qin SR, Qiu XL. Lyophilized paclitaxel magnetoliposomes as a potential drug delivery system for breast carcinoma via parenteral administration: In vitro and in vivo studies. Pharm Res. 2005; 22: 573-83.
13. Babincova M, Cicmanec P, Altanerova V, Altaner C, Babinec P. AC-magnetic field controlled drug release from magnetoliposomes: Design of a method for site-specific chemotherapy. Bioelectrochemistry. 2002; 55: 17-19.
14. Hassan EE, Gallo JM. Targeting anticancer drugs to the brain. I. Enhanced brain delivery of oxantrazole following administration in magnetic cationic microsperes. J Drug Targeting. 1993; 1: 7-14.
15. Jain TK, Morales MA, Sahoo SK, Leslie-Pelecky DL, Labhasetwar V. Iron oxide nanoparticles for sustained delivery of anticancer agents. Mol Pharm. 2005; 2: 194-205.
16. Fortin-Ripoche JP, Martina MS, Gazeau F et al. Magnetic targeting of magnetoliposomes to solid tumors with MR imaging monitoring in mice: feasibility. Radiology. 2006; 239: 415-24.
17. Suzuki M, Shinkai M, Honda H, Kobayashi T. Anticancer effect and immune induction by hyperthermia of malignant melanoma using magnetite cationic liposomes. Melanoma Res. 2003; 13: 129-35.
18. Hirao K, Sugita T, Kubo T et al. Targeted gene delivery to human osteocarcinoma cells with magnetic cationic liposomes under a magnetic field. Int J Oncol. 2003; 22: 1065-71.
19. 4 and gemcitabine enhance anti-tumor effect in pancreatic cancer xenograft mouse model. J Drug Target. 2007; 15: 445-53.
20. Wu J, Lee A, Lu Y, Lee RJ. Vascular targeting of doxorubicin using cationic liposomes. Int J Pharm. 2007; 337: 329-35.
21. Dandamudi S, Campbell RB. Development and characterization of magnetic cationic liposomes for targeting tumor microvasculature. Biochim Biophys Acta. 2007; 1768: 427-38.
22. Dandamudi S, Campbell RB. The drug loading, cytotoxicty and tumor vascular targeting characteristics of magnetite in magnetic drug targeting. Biomaterials. 2007; 28: 4673-83.
23. Maswadeh H, Demetzos C, Dimas K et al. Accumulation of vinblastine into transfersomes and liposomes in response to a transmembrane ammonium sulfate gradient and their cytotoxic/cytostatic activity in vitro. Anticancer Res. 2001;21: 2577-83.
24. Ellis A. Solutions to the problem of substitution of ERL 4221 for vinyl cyclohexene dioxide in spurr low viscosity embedding formulations. Microscopy Today. 2006: 32-3.
25. Krasnici S, Werner A, Eichhorn ME et al. Effect of the surface charge of liposomes on their uptake by angiogenic tumor vessels. Int J Cancer. 2003; 105: 561-7.
26. Nair S, Boczkowski D, Moeller B, Dewhirst M, Vieweg J, Gilboa E. Synergy between tumor immunotherapy and antiangiogenic therapy. Blood. 2003; 102: 964-71.
27. Pluen A, Boucher Y, Ramanujan S et al. Role of tumor-host interactions in interstitial diffusion of macromolecules: Cranial vs. subcutaneous tumors. Proc Natl Acad Sci U S A. 2001; 98: 4628-33.
28. Das SK, Sainsbury R. Malignant melanoma-An overview. Indian J Dermatol. 1975; 21: 12-20.
29. Murakami T, Cardones AR, Hwang ST. Chemokine receptors and melanoma metastasis. J Dermatol Sci. 2004; 36: 71-8.
30. Ishida T, Kundu RK, Yang E, Hirata K, Ho YD, Quertermous T. Targeted disruption of endothelial cell-selective adhesion molecule inhibits angiogenic processes in vitro and in vivo. J Biol Chem. 2003; 278: 34598-604.
31. Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst. 1990; 82: 4-6.
32. Folkman J. The role of angiogenesis in tumor growth. Semin Cancer Biol. 1992; 3: 65-71.
33. Campbell RB, Ying B, Kuesters GM, Hemphill R. Fighting cancer: From the bench to bedside using second generation cationic liposomal therapeutics. J Pharm Sci. 2009; 98: 411-29.
34. Lubbe AS, Bergemann C, Riess H et al. Clinical experiences with magnetic drug targeting: A phase I study with 4′-epidoxorubicin in 14 patients with advanced solid tumors. Cancer Res. 1996; 56: 4686-93.
35. Barry JW, Bookstein JJ, Alksne JF. Ferromagnetic embolization. Experimental evaluation. Radiology. 1981; 138: 341-9.
36. Zhou-Pan XR, Seree E, Zhou XJ. et al. Involvement Human Liver Cytochrome P450 3A in vinblastine metabolism: Drug interactions. Cancer Res. 1993; 53: 5121-6.
37. Fidler IJ. Regulation of neoplastic angiogenesis. J Natl Cancer Inst. 2001: 10-14.
38. Fidler IJ. Angiogenesis and cancer metastasis. Cancer J (Sudbury, Mass. 2000; 6 (Suppl. 2): S134-41.